Gene Edited Crops Regulation: US and EU Rules for 2026

For anyone commercialising a CRISPR-edited variety, gene edited crops regulation is no longer a settled question – it moved in both of the world’s biggest markets within the last two years. In the United States, a federal court set aside the exemptions that let many edited plants skip review. In the European Union, lawmakers finally adopted a dedicated framework for new genomic techniques after years of treating edited crops as conventional GMOs. A breeder who planned a launch against the old rules can find the ground has shifted under both feet. This guide explains where each market now stands, and why clearing the regulator is a different exercise from clearing the patents.

What Gene Edited Crops Regulation Actually Covers

Gene edited crops regulation decides whether a plant created with a tool like CRISPR can be field-tested, sold and planted – and under what conditions of review, labelling and traceability. It sits entirely separately from patents. A patent says who owns the method; regulation says whether the plant may reach the market at all. A variety can be perfectly clear of third-party patents and still be stuck in a multi-year authorisation queue, or clear of regulation and still blocked by a foundational editing patent it never licensed.

The deepest divide in global policy is whether a country regulates by process or by product. A process-based system asks how the plant was made – if genetic engineering was involved, it is regulated as such regardless of the result. A product-based system asks what the plant is – if the end result could have arisen through conventional breeding, it is treated like any other new variety. The United States leans product-based; the European Union has historically been firmly process-based. That single distinction explains almost every difference below.

• Process-based trigger: the technique used (gene editing) determines the regulatory burden.
• Product-based trigger: the characteristics of the final plant determine it, not the method.
• Most CRISPR edits introduce small changes that could, in principle, occur in nature or through conventional mutagenesis – which is exactly why the two systems reach opposite conclusions.

The US SECURE Rule and Its 2024 Reversal

In the United States, biotech crops are governed by a Coordinated Framework split across USDA (plant-pest and noxious-weed risk), the EPA (plant-incorporated protectants) and the FDA (food and feed safety). For gene-edited plants, the pivotal USDA rule was the 2020 SECURE rule – formally the Movement of Certain Genetically Engineered Organisms rule – which APHIS fully implemented in October 2021.

The SECURE rule introduced exemptions: certain gene-edited plants were exempt from regulation because the same change could have been achieved through conventional breeding, and APHIS reasoned they were unlikely to pose an increased plant-pest risk. For developers, those categorical exemptions were the fast lane – an edited variety that qualified could move toward market without a full regulatory-status review.

That fast lane narrowed sharply. On 2 December 2024, a federal court in California held that the 2020 rulemaking was arbitrary and capricious under the Administrative Procedure Act, finding APHIS had dismissed concerns about the potential weediness of genetically engineered plants without adequate analysis. Following the ruling, APHIS set aside its categorical exemptions and reverted to the pre-2020 regulatory framework for genetically engineered organisms.

The practical message for 2026 is blunt: a US developer can no longer assume an edited variety is automatically exempt. The safer assumption is that the plant may need an APHIS regulatory-status review, and that time and cost should be budgeted into the launch plan rather than waved through.

How the EU Regulates Gene-Edited Plants: the NGT Regulation

The European Union took the opposite starting point. In its 2018 Confederation paysanne judgment (Case C-528/16), the Court of Justice held that organisms obtained by directed mutagenesis techniques – including modern gene editing – fall within the GMO Directive, subjecting them to the full authorisation, labelling and traceability regime. For a decade that made Europe one of the hardest markets in the world for an edited crop.

That is now changing. After the European Council agreed a common position in March 2025, the Council and Parliament struck a provisional deal on 4 December 2025 on a dedicated framework for plants produced with new genomic techniques (NGTs). The regulation creates two categories. NGT-1 plants – those considered equivalent to conventional plants – are released from most of the GMO regime and will not carry GMO labelling. NGT-2 plants remain under the strict GMO framework, with mandatory labelling and traceability, but benefit from an accelerated risk assessment.

Timing is the catch. The framework was adopted at Council level in 2026, but it is not expected to apply until around mid-2028. Until then, gene-edited plants in the EU still fall under the existing GMO authorisation rules established by the 2018 judgment. A breeder planning a near-term European launch therefore cannot yet rely on the NGT-1 conventional treatment – the rule exists on paper before it exists in practice.

• NGT-1: treated as conventional, no GMO label, lightest path – once the rule applies.
• NGT-2: full GMO regime with labelling and traceability, plus an accelerated assessment.
• Transition gap: the old GMO rules govern until the NGT regulation applies (~2028).

Patents Versus Regulation: Two Separate Clearances

Even a fully approved variety can be enjoined if it infringes a foundational editing patent. Gene editing is one of the most heavily patented areas in the life sciences: the CRISPR landscape now runs to more than 23,000 patent families, and the foundational plant-applicable Cas9 estates are controlled by a short list of institutions including the Broad Institute and the University of California.

Here agritech is unusually favourable. Rather than a fragmented thicket with no one to pay, the foundational plant CRISPR estate can be reached through Corteva’s consolidated sublicensing route, which packages the foundational Cas9 plant patents together – the same route by which companies such as J.R. Simplot have taken CRISPR licences. That turns the single largest part of the patent landscape from an existential unknown into a priced licence. The genuine blockers are usually the trait-specific claims over the particular gene, edit and phenotype, which need a claim-by-claim freedom-to-operate read.

The two gates move independently. We walked through exactly how a breeder runs both in parallel in our agritech freedom-to-operate case study, and the underlying method is set out on our freedom-to-operate analysis service. The lesson that surprises most teams is that after the 2024 US reversal and before the 2028 EU NGT start, it is often the regulator, not the patent, that sets the launch date.

What Breeders Should Do Now

Treat gene edited crops regulation as a live variable in the commercial plan, not a box ticked years ago. The rules in both flagship markets changed recently and in opposite directions, and the smart sequence follows the regulation as much as the science.

1. Confirm current status, not the status you remember – the US SECURE exemptions were set aside in December 2024, so re-check whether your variety now needs an APHIS review.
2. Map your edit to the EU NGT categories (NGT-1 vs NGT-2) but plan around the old GMO rules until the regulation applies around 2028.
3. Run a patent freedom-to-operate clearance in parallel, separating the licensable foundational CRISPR layer from the trait-specific claims you must design around or negotiate.
4. Sequence launch markets by regulatory readiness, not just market size – entering the US review early and timing the EU launch to the NGT start can save a wasted authorisation spend.
5. Keep a documented clearance file covering both gates, so a regulatory challenge or an infringement claim meets an evidenced position rather than a scramble.

A variety that clears both the regulator and the patents is a variety you can actually sell. Clearing only one is the most common – and most expensive – mistake in agritech commercialisation.

Clear Your Gene-Edited Variety Before You Launch

PerspireIP runs the patent half of the clearance – a freedom-to-operate read that separates the licensable foundational CRISPR estate from the trait-specific claims you must address – so your regulatory and legal teams work from the same cleared position. See our freedom-to-operate analysis service or talk to our team.

Frequently Asked Questions